Autor: |
Williams, Bryan, MacDonald, Thomas M, Morant, Steve V, Webb, David J, Sever, Peter, McInnes, Gordon T, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Padmanabhan, Sandosh, Mackenzie, Isla S, Salsbury, Jackie, Brown, Morris J, Balakrishnan, K, Burton, T, Cannon, J, Collier, D, Coughlan, C, D'Souza, R, Enobakhare, E, Findlay, E, Gardiner-Hill, C, Gupta, P, Helmy, J, Helmy, C, Hobbs, L, Hobbs, R, Hood, S, Iles, R, Kean, S, Kwok, S, Lacy, P, MacIntyre, I, Mackay, J, Markandu, N, Martin, U, McCallum, L, McCann, G, McGinnis, A, Melville, V, Muir, S, Myint, KS, Nazir, S, Palmer, J, Papworth, R, Rutkowski, K, Saxena, M, Schumann, A, Soran, H, Stanley, A, Thom, S, Webb, A, White, C, Wilson, R, Zak, A |
Zdroj: |
The Lancet Diabetes & Endocrinology; June 2018, Vol. 6 Issue: 6 p464-475, 12p |
Abstrakt: |
In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. |
Databáze: |
Supplemental Index |
Externí odkaz: |
|